<DOC>
	<DOCNO>NCT00741910</DOCNO>
	<brief_summary>Study CNI-1493-CD06 open , single-arm extension study CD03 CD05 . CDAI efficacy measure assess study . The safety multiple course semapimod determine incidence clinical laboratory adverse event .</brief_summary>
	<brief_title>Extension Study Semapimod 60 mg IV x 3 Days</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Semapimod</mesh_term>
	<criteria>The study open patient satisfactorily complete either study CNI1493CD03 CNI1493CD05 . Initial entry criterion : 1 . Patients satisfactorily complete either study CNI1493CD03 CD05 eligible participation study . Satisfactory completion define follow : 1 . The patient complete 5 treatment course previous trial . 2 . The patient respond treatment , define decrease CDAI least 70 point original baseline ( prior treatment study CD02 CD04 ) last assessment study CD03 CD05 , respectively . The decrease attributable semapimod treatment . Thus , patient whose response attributable antiCrohn 's disease therapy include . 3 . The patient adverse event &gt; grade 2 felt probably definitely relate study medication . 4 . The patient meet discontinuation criterion previous trial . 2 . Patients sign inform consent specifically study , addition consent previous study , CNI1493CD02 CD03 , CNI1493CD04 CD05 . 3 . Patients could take investigational therapy course study . 4 . Men woman childbearing potential use barrier method ( diaphragm condom ) contraception continue least 3 month last study medication . It strongly recommend two form use . 5 . Patients able adhere study visit schedule and/or protocol requirement . Could meet exclusion criterion CD02 , 03 , 04 05 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>TNF-alpha inhibitor</keyword>
	<keyword>MAP Kinase inhibitor</keyword>
	<keyword>CNI-1493</keyword>
</DOC>